2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155979
    SARS-CoV-2 3CLpro-IN-16 352659-40-6 98%
    SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro.
    SARS-CoV-2 3CLpro-IN-16
  • HY-155980
    SARS-CoV-2 3CLpro-IN-17 3032604-33-1 98%
    SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322 μM).
    SARS-CoV-2 3CLpro-IN-17
  • HY-155981
    SARS-CoV-2 3CLpro-IN-18 3032604-29-5 98%
    SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC50= 2.499 μM) with low cytotoxicity (CC50 > 200 μM).
    SARS-CoV-2 3CLpro-IN-18
  • HY-156008
    SARS-CoV-2-IN-58 3052692-38-0 98%
    SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against SARS-CoV-2 (EC50: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 Mpro with an IC50 of 0.35 μM.
    SARS-CoV-2-IN-58
  • HY-156014
    qsl-304 98%
    qsl-304 is a DNA gyrase B inhibitor. qsl-304 is an antibacterial agent, with an IC50 of 31.23 mg/mL against the Staphylococcus aureus sa-P2003.
    qsl-304
  • HY-156028
    FIKK9.1-IN-1 1448523-50-9 98%
    FIKK9.1-IN-1 (Compound 1) is a FIKK9.1 inhibitor. FIKK9.1-IN-1 interacts with the ATP?binding residues in FIKK9.1. FIKK9.1-IN-1 is an antimalarial agent (IC50: 2.68 μg/mL) and disrupts the parasite life cycle and leads to the death of parasites.
    FIKK9.1-IN-1
  • HY-15602C
    Ledipasvir hydrochloride 2128695-48-5 98%
    Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM.
    Ledipasvir hydrochloride
  • HY-15602S
    Ledipasvir-d6 2050041-12-6 99.0%
    Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM.
    Ledipasvir-d6
  • HY-156051
    Tetrazolast 95104-27-1 98%
    Tetrazolast is a HCV inhibitor with the inhibitory activity ranging from 5% to 20%, extracted from patent WO2005030774.
    Tetrazolast
  • HY-156063
    (2R,4R)-UCB7362 2610631-17-7 98%
    (2R,4R)-UCB7362 is the (2R,4R) isomer of UCB7362 (HY-151568). UCB7362 is an inhibitor of plasma proteinase X (PMX) with antimalarial activity.
    (2R,4R)-UCB7362
  • HY-156090
    PK-10 3074451-41-2 98%
    PK-10 is a synergistic antibacterial agent of Fluconazole (HY-B0101) and has strong antifungal activity against a variety of Fluconazole-resistant Candida albicans strains. PK-10 combined with Fluconazole can inhibit hyphae formation and induce the accumulation of reactive oxygen species. It further causes damage to mitochondrial membrane potential, reduces intracellular ATP content, and leads to mitochondrial dysfunction.
    PK-10
  • HY-156105
    8304-vs 98%
    8304-vs is a macrocyclic anti-Plasmodial agent that covalently and irreversibly targets the Plasmodium proteasome. 8304-vs effectively inhibits the growth of Plasmodium falciparum.
    8304-vs
  • HY-156122
    DHFR-IN-8 3032441-09-8 98%
    DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=15.6 ng/mL) in mouse models of systemic infection and thigh infection.
    DHFR-IN-8
  • HY-156123
    DHFR-IN-9 3032441-13-4 98%
    DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days).
    DHFR-IN-9
  • HY-156132
    DNDI-0690 2097881-13-3 98%
    DNDI-0690 is a potent orally active analogue of DNDI-VL-2098, exhibiting potent activity against cutaneous leishmaniasis (CL). DNDI-0690 shows potent in vitro activity against CL-causing Leishmania species (EC50 = 0.17 μM against visceral leishmaniasis (VL), and < 5 μM against CL-causing species). DNDI-0690 exerts effects in a mouse model of L. major CL. DNDI-0690 can be used for CL research.
    DNDI-0690
  • HY-156149
    CYP51/PD-L1-IN-1 3032386-49-2 98%
    CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death.
    CYP51/PD-L1-IN-1
  • HY-156150
    CYP51/PD-L1-IN-2 3032386-58-3 98%
    CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death.
    CYP51/PD-L1-IN-2
  • HY-156151
    CYP51/PD-L1-IN-3 3032386-59-4 98%
    CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death.
    CYP51/PD-L1-IN-3
  • HY-156189
    CcpA-IN-1 2702277-62-9 98%
    CcpA-IN-1 is a Staphylococcus aureus antibiotic. CcpA-IN-1 has significant bactericidal activity (MICS=460 nM).
    CcpA-IN-1
  • HY-156241
    Meliadubin B 98%
    Meliadubin B is a natural triterpenoid with significant inflammatory inhibition effect toward superoxide anion generation in human neutrophils (EC50 of 5.54 μM). Meliadubin B inhibits inducible nitric oxide synthase. Meliadubin B shows remarkable inhibition against the rice pathogenic fungus Magnaporthe oryzae with IC50 of 182.50 μM.
    Meliadubin B
Cat. No. Product Name / Synonyms Application Reactivity